EUCTR2008-006785-29-FR进行中（未招募）1 期
A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-cause mortality in adult patients with aneurysmal subarachnoid hemorrhage treated by endovascular coiling. - CONSCIOUS 3
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,470
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Males and females aged 18 to 75 years (inclusive).
- •2.Patients with a ruptured saccular aneurysm, confirmed by angiography (digital subtraction angiography [DSA] or computed tomography angiography [CTA], investigator’s assessment), and which has been successfully* secured by endovascular coiling. The time of aneurysm rupture must be known or possible to estimate with a reasonable degree of certainty.
- •3.World Federation of Neurological Surgeons (WFNS) grade I–IV measured prior to the endovascular coiling procedure, and which does not worsen to grade V post-procedure (based on regular Glasgow Coma Scale [GCS])†
- •4.Patients with any thick clot (short axis >= 4 mm) on baseline CT scan (investigator’s assessment).
- •5.Women of childbearing potential must have a negative serum pregnancy test and must use a reliable method of contraception during the 12 weeks following study drug discontinuation.
- •6.Written informed consent to participate in the study must be obtained from the patient or a legal representative prior to initiation of any study-mandated procedure and randomization.
- •* A successful procedure is defined as a procedure after which the end of procedure DSA indicates that the coiling was complete or adequate (i.e., more than 50% of the volume of the aneurysm is filled in by coiling material, investigator's assessment) and when the patient is not scheduled for a 2nd procedure on the ruptured aneurysm within 12 weeks post-aSAH.
- •†Patients must be evaluable for WFNS grade prior to the endovascular coiling procedure. Patients who cannot be assessed for WFNS post procedure due to a requirement for uninterrupted sedation (e.g., for high or unstable intracranial pressure [ICP]) may be included in the study provided that a CT scan is performed at least 12 hours post-procedure, but prior to randomization, ruling out any large procedure-related infarct.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patients with subarachnoid hemorrhage (SAH) due to causes other than a saccular aneurysm (e.g., trauma or rupture of fusiform or mycotic aneurysms).
- •2.Patients with giant aneurysms (height or width >= 25 mm).
- •3.Patients with intraventricular or intracerebral blood, in the absence of subarachnoid blood, or with only a thin clot (short axis < 4 mm).
- •4.Presence of cerebral vasospasm seen on angiography (investigator’s assessment) prior to the endovascular coiling procedure. (Intraprocedural cerebral vasospasm is not an exclusion criterion).
- •5.Patients who experienced a major complication during the endovascular coiling procedure, such as massive intracranial bleeding, intracranial thromboembolism, coil migration, aneurysm perforation or rupture, arterial dissection, major arterial occlusion, a large territorial cerebral infarct defined as involving > 1/3 of a vascular territory, or a new major neurological deficit post-procedure (e.g., hemiplegia or aphasia lasting >= 12 hours post-aneurysm coiling).*
- •6.Patients who have had their current ruptured aneurysm previously secured (successfully or not) by clipping.
- •7.Patients coiled with coiling material, which has not been approved by local health authorities.
- •8.Use of liquid embolism aneurysmal treatment or flow diverting device.
- •9.Patients with several aneurysms among which the ruptured one cannot be identified with certainty and which are not all secured during the coiling procedure.
- •10.Patients with no DSA at end-of-procedure.
- •11.Patients planned to have another securing procedure for any aneurysm after randomization and prior Week 12 post-aSAH.
- •12.Patients for whom study drug cannot be started within 56 hours after the aneurysm rupture.
- •13.Patients for whom it is known, at the time of screening, that certain follow-up, or protocol-mandated imaging assessments will not be feasible.
- •14.Patients with hypotension (systolic blood pressure (SBP) <= 90 mmHg) that is refractory to treatment.
- •15.Patients with aspiration pneumonia.
- •16.Patients with pulmonary edema or severe cardiac failure requiring inotropic support at the time of randomization.
- •17.Any severe or unstable concomitant condition or disease (e.g., known significant neurological deficit, cancer, hematological, or coronary disease), or chronic condition (e.g., psychiatric disorder), which, in the opinion of the investigator, would affect the assessment of the safety or efficacy of the study drug.
- •18.Significant kidney and/or liver disease, as defined by plasma creatinine >= 2.5 mg/dL (221 µmol/l) and/or total bilirubin > 3 mg/dL (51.3 µmol/l) measured at the local laboratory.
- •19.Patients receiving i.v. nimodipine or i.v. nicardipine must have these drugs discontinued at least 4 hours prior to initiation of the study treatment.
- •20.Patients who have received i.v. fasudil within the 24-hour period immediately preceding the planned start of study drug initiation.
- •21.Patients starting statins less than 2 weeks prior to admission must have them discontinued prior to study drug initiation.
- •22.Patients receiving cyclosporin A or other calcineurin inhibitors (e.g., tacrolimus), or patients for whom it is known at the time of randomization that these medications will be started during the study drug infusion period.
- •23.Patients who have received an investigational product including investigational coil material within 28 days prior to randomization or those who have already participated in the current study.
- •24.Patients unlikely to comply w
研究者
相似试验
进行中（未招募）
1 期
Clinical research study with clazosentan to evaluate its effects on preventing complications due to the narrowing of the blood vessels (vasospasm) in the brain, caused by bleeding onto the surface of the braiAneurysmal Subarachnoid HemorrhageMedDRA version: 21.1Level: PTClassification code 10039330Term: Ruptured cerebral aneurysmSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: PTClassification code 10042316Term: Subarachnoid haemorrhageSystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-000241-39-ATIdorsia Pharmaceuticals Ltd400
进行中（未招募）
不适用
A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-cause mortality in adult patients with aneurysmal subarachnoid hemorrhage treated by surgical clipping. - CONSCIOUS 2Indication: Aneurysmal subarachnoid hemorrhageMedDRA version: 9.1Level: LLTClassification code 10042318Term: Subarachnoid haemorrhage NOSEUCTR2007-002584-27-DKActelion Pharmaceuticals Ltd.1,146
进行中（未招募）
不适用
A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-cause mortality in adult patients with aneurysmal subarachnoid hemorrhage treated by endovascular coiling. - CONSCIOUS 3Indication: Subarachnoid aneurysmal hemorrhageMedDRA version: 11Level: LLTClassification code 10042316Term: <Manually entered code. Term in E.1.1>EUCTR2008-006785-29-SEActelion Pharmaceuticals Ltd.1,470
进行中（未招募）
不适用
A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-cause mortality in adult patients with aneurysmal subarachnoid hemorrhage treated by surgical clipping. - CONSCIOUS 2EUCTR2007-002584-27-SEActelion Pharmaceuticals Ltd.1,146
进行中（未招募）
1 期
Clinical research study with clazosentan to evaluate its effects on preventing complications due to the narrowing of the blood vessels (vasospasm) in the brain, caused by bleeding onto the surface of the braiAneurysmal Subarachnoid HemorrhageMedDRA version: 20.1Level: PTClassification code 10039330Term: Ruptured cerebral aneurysmSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: PTClassification code 10042316Term: Subarachnoid haemorrhageSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2018-000241-39-HUIdorsia Pharmaceuticals Ltd400